To study safety, tolerability and pharmacokinetics of AZD1305 in healthy male Japanese subjects

Study identifier:D3191C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A single-centre, single-blind, randomised, placebo-controlled, phase I study to assess the safety, tolerability and pharmacokinetics after single ascending intravenous doses of AZD1305 in healthy male Japanese subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD1305, Placebo

Sex

Male

Actual Enrollment

36

Study type

Interventional

Age

20 Years - 40 Years

Date

Study Start Date: 01 Jul 2008
Primary Completion Date: -
Study Completion Date: 01 Oct 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria